You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
GenMark said its ePlex molecular diagnostic product revenue for Q4 was $45.4 million, an increase of 138 percent over the fourth quarter of 2019.
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
The company is also continuing to expand its digital technology offering to help clinicians track their patients' health more easily.
For the 12 months ended Dec. 31, 2020, Biocartis' revenues rose to €43.1 million ($52.7 million) from €37.4 million in 2019.
The firm said its revenues for the three months ended Dec. 31, 2020 were $78.3 million compared to $62.9 million in the same quarter of 2019.
The immune cell sequencing company beat Wall Street estimates on the top line, but missed on the bottom line for both Q4 and full-year 2020.
The company reported $58.6 million in total revenues for the quarter and said testing services revenues rose 73 percent year over year.
The firm reported revenues of $126.0 million for the three-month period ended Dec. 31, 2020, up from $106.9 million in the same period last year.
The firm guided for 2021 revenue growth of between 5 percent and 8 percent, citing "a persistently uncertain business environment."
